Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

2020501 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 21, Issue 9, pp. 1234-1243

Field-Weighted Citation Impact: 61.55